Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Cyclacel Pharmaceuticals (United Kingdom) | Researchclopedia

Back to institutions

Cyclacel Pharmaceuticals (United Kingdom)

Dundeecompany

195

Works

39,357

Citations

105

h-index

Top Research Topics

Cancer-related Molecular Pathways Advanced Breast Cancer Therapies Microtubule and mitosis dynamics

Top Researchers

Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

5,467 works263,924 citationsh-index: 230

Recent Research

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer.

Mohammad Zokaasadi,Wylie K. Watlington,et al.

20250 citations

Chronic Lymphocytic Leukemia Research

Ubiquitin and proteasome pathways

Acute Myeloid Leukemia Research

Protein Degradation and Inhibitors

Biochemical and Molecular Research

Chemical Synthesis and Analysis

Cancer therapeutics and mechanisms

Cancer Mechanisms and Therapy

Cancer, Hypoxia, and Metabolism

Kenneth C. Anderson Boston University

3,074 works167,471 citationsh-index: 199

Jörge E. Cortes Augusta University Health

3,571 works143,300 citationsh-index: 179

Christopher D.�M. Fletcher Brigham and Women's Hospital

845 works108,131 citationsh-index: 157

Nikhil C. Munshi Boston University

1,578 works95,628 citationsh-index: 152

Shaji Kumar Mayo Clinic

2,198 works93,562 citationsh-index: 135

Dual targeting of conserved cell cycle and transcription programs in advanced colorectal cancer by fadraciclib

Mohammad Zokaasadi,Wylie K. Watlington,et al.

20250 citations

Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors <i>In Vivo</i>

Claudia Kettlun,Daniel L. Galvan,et al.

20240 citations

A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.

Miguel A. Villalona‐Calero,Do‐Youn Oh,et al.

20245 citations

Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.

Mohammad Zokaasadi,Erdem Altunel,et al.

20241 citations

Author's addendum to the article: Fingolimod: Assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteria

Wendy Greenwood,Victoria Dickinson,et al.

20232 citations